Abstract:The growing threat of bacterial resistance to antibiotics has led to the rise of anti-virulence strategies as a promising approach. These strategies aim to disarm bacterial pathogens and improve their clearance by the host immune system. Lipopolysaccharide, a key virulence factor in Gram-negative bacteria, has been identified as a potential target for anti-virulence agents. In this study, we focus on inhibiting HldA and HldE, bacterial enzymes from the heptose biosynthesis pathway, which plays a key role in lipopolysaccharide biosynthesis. We present the synthesis of two fluorinated non-hydrolysable heptose phosphate analogues. Additionally, the inhibitory activity of a family of eight heptose phosphate analogues against HldA and HldE was assessed. This evaluation revealed inhibitors with affinities in the low μM range, with the most potent compound showing inhibition constant values of 15.4 μM for HldA and 16.9 μM for HldE. The requirement for a phosphate group at the C-7 position was deemed essential for inhibitory activity, while the presence of a hydroxy anomeric group was found to be beneficial, a phenomenon rationalized through computational modeling. Additionally, the introduction of a single fluorine atom α to the phosphonate moiety conferred a slight advantage for inhibition. These findings suggest that mimicking the structure of d-glycero-β-d-manno-heptose 1,7-bisphosphate, the product of the phosphorylation step in heptose biosynthesis, could be a promising strategy to disrupt this biosynthetic pathway. In terms of the in vivo effects, these heptose phosphate analogues neither demonstrated significant LPS-disrupting effects nor exhibited growth inhibitory activity on their own. Additionally, they did not alter the susceptibility of bacteria to hydrophobic antibiotics. The highly charged nature of these molecules may hinder their ability to penetrate the bacterial cell wall. To overcome this limitation, alternative strategies such as incorporating protecting groups that facilitate their entry and can subsequently be cleaved within the bacterial cytoplasm could be explored.

Exploring the UDP pocket of LpxC through amino acid analogs

Altered architecture of substrate binding region defines the unique specificity of UDP-GalNAc 4-epimerases

A High-Throughput–Compatible Fluorescence Anisotropy-Based Assay for Competitive Inhibitors of Escherichia Coli UDP-N-Acetylglucosamine Acyltransferase (Lpxa)

Exploring marine-derived bioactive compounds for dual inhibition of Pseudomonas aeruginosa LpxA and LpxD: integrated bioinformatics and cheminformatics approaches

Synthesis, Structure, and SAR of Tetrahydropyran-Based LpxC Inhibitors.

Preclinical safety and efficacy characterization of an LpxC inhibitor against Gram-negative pathogens

[Socioeconomic and demographic indicators associated with functional disability in the elderly].

Crystal structure of A. aeolicus LpxC with bound product suggests alternate deacetylation mechanism

The UK version of the Seattle Angina Questionnaire (SAQ-UK): reliability, validity and responsiveness.

A comprehensive review of recent developments in the gram-negative bacterial UDP-2,3-diacylglucosamine hydrolase (LpxH) enzyme

Structural Insights into the Lipopolysaccharide Transport (Lpt) System as a Novel Antibiotic Target

Structure of the essential inner membrane lipopolysaccharide-PbgA complex

Design, synthesis, and in vitro biological evaluation of meta -sulfonamidobenzamide-based antibacterial LpxH inhibitors

Sonographically guided metallic clip placement after core needle biopsy of the breast.

Exploring fluorinated heptose phosphate analogues as inhibitors of HldA and HldE, key enzymes in the biosynthesis of lipopolysaccharide

Lipopeptide antibiotics disrupt interactions of undecaprenyl phosphate with UptA

The Complex Structure of Protein AaLpxC from Aquifex aeolicus with ACHN-975 Molecule Suggests an Inhibitory Mechanism at Atomic-Level against Gram-Negative Bacteria

A new antibiotic traps lipopolysaccharide in its intermembrane transporter

Design, synthesis and evaluation of novel LpxC inhibitors containing a hydrazone moiety as Gram-negative antibacterial agents

Common and varied molecular responses of Escherichia coli to five different inhibitors of the lipopolysaccharide biosynthetic enzyme LpxC

A pathway-directed positive growth restoration assay to facilitate the discovery of lipid A and fatty acid biosynthesis inhibitors in Acinetobacter baumannii